172 related articles for article (PubMed ID: 34289337)
1. Intravitreal Antivascular Endothelial Growth Factor Treatment for Inflammatory Choroidal Neovascularization in Noninfectious Uveitis.
Woronkowicz M; Niederer R; Lightman S; Tomkins-Netzer O
Am J Ophthalmol; 2022 Apr; 236():281-287. PubMed ID: 34289337
[TBL] [Abstract][Full Text] [Related]
2. Etiology, Treatment Patterns, and Outcomes for Choroidal Neovascularization in the Pediatric Population: An Intelligent Research in Sight (IRIS®) Registry Study.
Finn AP; Fujino D; Lum F; Rao P
Ophthalmol Retina; 2022 Feb; 6(2):130-138. PubMed ID: 34091079
[TBL] [Abstract][Full Text] [Related]
3. ANTIANGIOGENICS IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LASER IN CENTRAL SEROUS CHORIORETINOPATHY.
Chhablani J; Pichi F; Silva R; Casella AM; Murthy H; Banker A; Nowilaty SR; Carrai P; Nucci P; Arevalo JF;
Retina; 2016 May; 36(5):901-8. PubMed ID: 27115855
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
6. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis.
Tran TH; Fardeau C; Terrada C; Ducos De Lahitte G; Bodaghi B; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2008 Dec; 246(12):1685-92. PubMed ID: 18682970
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in inflammatory eye disease.
Lott MN; Schiffman JC; Davis JL
Am J Ophthalmol; 2009 Nov; 148(5):711-717.e2. PubMed ID: 19660732
[TBL] [Abstract][Full Text] [Related]
13. Pediatric choroidal neovascularization: Etiology and treatment outcomes with anti-vascular endothelial growth factors.
Ranjan R; Salian R; Verghese S; Manayath GJ; D'Souza P; Kanakath AV; Shah PK; Saravanan VR; Venkatapathy N
Eur J Ophthalmol; 2022 Jul; 32(4):2355-2367. PubMed ID: 34615395
[TBL] [Abstract][Full Text] [Related]
14. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration.
Stem MS; Moinuddin O; Kline N; Thanos A; Rao P; Williams GA; Hassan TS
JAMA Ophthalmol; 2018 Jul; 136(7):820-823. PubMed ID: 29800991
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia.
Rhéaume MA; Sebag M
Can J Ophthalmol; 2008 Oct; 43(5):576-80. PubMed ID: 18982035
[TBL] [Abstract][Full Text] [Related]
17. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
18. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
Veritti D; Sarao V; Lanzetta P
J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
